Cholangiocarcinoma

S. A. Ahrendt, A. Nakeeb, H. A. Pitt

Research output: Contribution to journalArticle

94 Citations (Scopus)

Abstract

Despite overall advances in the ability to diagnose and treat patients with cholangiocarcinoma, the prognosis for patients with this malignancy remains poor. Further improvements in the survival of patients with cholangiocarcinoma will come with the early diagnosis of these lesions. New molecular techniques should improve the ability to screen high-risk patients, such as those with primary sclerosing chollangitis, hepatolithiasis, choledochal cysts, and ulcerative colitis. Improvements in imaging will continue, and spiral CT scanning, duplex ultrasonography, MR imaging and, perhaps, PET scans will improve the ability to stage patients with cholangiocarcinoma noninvasively. Complete surgical resection remains the only curative treatment for malignancies of the biliary tract. Aggressive surgical approaches are likely to continue, and the challenge remains in being able to perform these procedures safely in jaundiced and sometimes septic patients. For patients with unresectable lesions, the optimal form of palliation, whether surgical or nonsurgical, remains to be defined. Finally, multicenter, prospective, randomized trials of chemoradiation need to be performed to delineate an effective adjuvant therapy more precisely, and to improve the overall prognosis of patients with cholangiocarcinoma.

Original languageEnglish (US)
Pages (from-to)191-218
Number of pages28
JournalClinics in Liver Disease
Volume5
Issue number1
DOIs
StatePublished - Jan 1 2001

Fingerprint

Cholangiocarcinoma
Choledochal Cyst
Spiral Computed Tomography
Biliary Tract
Jaundice
Ulcerative Colitis
Positron-Emission Tomography
Early Diagnosis
Ultrasonography
Neoplasms
Survival
Therapeutics

ASJC Scopus subject areas

  • Hepatology

Cite this

Cholangiocarcinoma. / Ahrendt, S. A.; Nakeeb, A.; Pitt, H. A.

In: Clinics in Liver Disease, Vol. 5, No. 1, 01.01.2001, p. 191-218.

Research output: Contribution to journalArticle

Ahrendt, S. A. ; Nakeeb, A. ; Pitt, H. A. / Cholangiocarcinoma. In: Clinics in Liver Disease. 2001 ; Vol. 5, No. 1. pp. 191-218.
@article{9f5fb00cadfb429ebd7df7b2909a966c,
title = "Cholangiocarcinoma",
abstract = "Despite overall advances in the ability to diagnose and treat patients with cholangiocarcinoma, the prognosis for patients with this malignancy remains poor. Further improvements in the survival of patients with cholangiocarcinoma will come with the early diagnosis of these lesions. New molecular techniques should improve the ability to screen high-risk patients, such as those with primary sclerosing chollangitis, hepatolithiasis, choledochal cysts, and ulcerative colitis. Improvements in imaging will continue, and spiral CT scanning, duplex ultrasonography, MR imaging and, perhaps, PET scans will improve the ability to stage patients with cholangiocarcinoma noninvasively. Complete surgical resection remains the only curative treatment for malignancies of the biliary tract. Aggressive surgical approaches are likely to continue, and the challenge remains in being able to perform these procedures safely in jaundiced and sometimes septic patients. For patients with unresectable lesions, the optimal form of palliation, whether surgical or nonsurgical, remains to be defined. Finally, multicenter, prospective, randomized trials of chemoradiation need to be performed to delineate an effective adjuvant therapy more precisely, and to improve the overall prognosis of patients with cholangiocarcinoma.",
author = "Ahrendt, {S. A.} and A. Nakeeb and Pitt, {H. A.}",
year = "2001",
month = "1",
day = "1",
doi = "10.1016/S1089-3261(05)70161-6",
language = "English (US)",
volume = "5",
pages = "191--218",
journal = "Clinics in Liver Disease",
issn = "1089-3261",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Cholangiocarcinoma

AU - Ahrendt, S. A.

AU - Nakeeb, A.

AU - Pitt, H. A.

PY - 2001/1/1

Y1 - 2001/1/1

N2 - Despite overall advances in the ability to diagnose and treat patients with cholangiocarcinoma, the prognosis for patients with this malignancy remains poor. Further improvements in the survival of patients with cholangiocarcinoma will come with the early diagnosis of these lesions. New molecular techniques should improve the ability to screen high-risk patients, such as those with primary sclerosing chollangitis, hepatolithiasis, choledochal cysts, and ulcerative colitis. Improvements in imaging will continue, and spiral CT scanning, duplex ultrasonography, MR imaging and, perhaps, PET scans will improve the ability to stage patients with cholangiocarcinoma noninvasively. Complete surgical resection remains the only curative treatment for malignancies of the biliary tract. Aggressive surgical approaches are likely to continue, and the challenge remains in being able to perform these procedures safely in jaundiced and sometimes septic patients. For patients with unresectable lesions, the optimal form of palliation, whether surgical or nonsurgical, remains to be defined. Finally, multicenter, prospective, randomized trials of chemoradiation need to be performed to delineate an effective adjuvant therapy more precisely, and to improve the overall prognosis of patients with cholangiocarcinoma.

AB - Despite overall advances in the ability to diagnose and treat patients with cholangiocarcinoma, the prognosis for patients with this malignancy remains poor. Further improvements in the survival of patients with cholangiocarcinoma will come with the early diagnosis of these lesions. New molecular techniques should improve the ability to screen high-risk patients, such as those with primary sclerosing chollangitis, hepatolithiasis, choledochal cysts, and ulcerative colitis. Improvements in imaging will continue, and spiral CT scanning, duplex ultrasonography, MR imaging and, perhaps, PET scans will improve the ability to stage patients with cholangiocarcinoma noninvasively. Complete surgical resection remains the only curative treatment for malignancies of the biliary tract. Aggressive surgical approaches are likely to continue, and the challenge remains in being able to perform these procedures safely in jaundiced and sometimes septic patients. For patients with unresectable lesions, the optimal form of palliation, whether surgical or nonsurgical, remains to be defined. Finally, multicenter, prospective, randomized trials of chemoradiation need to be performed to delineate an effective adjuvant therapy more precisely, and to improve the overall prognosis of patients with cholangiocarcinoma.

UR - http://www.scopus.com/inward/record.url?scp=0035140313&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035140313&partnerID=8YFLogxK

U2 - 10.1016/S1089-3261(05)70161-6

DO - 10.1016/S1089-3261(05)70161-6

M3 - Article

C2 - 11218916

AN - SCOPUS:0035140313

VL - 5

SP - 191

EP - 218

JO - Clinics in Liver Disease

JF - Clinics in Liver Disease

SN - 1089-3261

IS - 1

ER -